Results overview: Found 7 records in 0.03 seconds.
Articles, 6 records found
Research literature, 1 records found
Articles 6 records found  
1.
22 p, 4.7 MB Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples / Olivan, M (Hospital Universitari Vall d'Hebron) ; García, Marta (Institut de Recerca Sant Joan de Déu) ; Suárez, Leticia (Hospital Universitari Vall d'Hebron) ; Guiu, Marc (Institut de Recerca Biomèdica) ; Gros, Laura (Hospital Universitari Vall d'Hebron) ; Méndez Fernández, Olga (Hospital Universitari Vall d'Hebron) ; Rigau, Marina (Hospital Universitari de Bellvitge) ; Reventós, Jaume (Hospital Universitari de Bellvitge) ; Segura, Miguel F. (Hospital Universitari Vall d'Hebron) ; de Torres, Inés (Hospital Universitari Vall d'Hebron) ; Planas, Jacques (Hospital Universitari Vall d'Hebron) ; de la Cruz, Xavier (Hospital Universitari Vall d'Hebron) ; Gomis, Roger R. (Hospital Universitari de Bellvitge) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Rodríguez-Barrueco, Ruth (Hospital Universitari de Bellvitge) ; Santamaría, Anna (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. [...]
2021 - 10.3390/cancers13246202
Cancers, Vol. 13 (december 2021)  
2.
14 p, 2.2 MB A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand / Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Borque-Fernando, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Triquell, Marina (Hospital Universitari Vall d'Hebron) ; Campistol, Miriam (Hospital Universitari Vall d'Hebron) ; Celma, Ana (Hospital Universitari Vall d'Hebron) ; Regis, Lucas (Hospital Universitari Vall d'Hebron) ; Abascal, Jose Maria (Parc de Salut MAR de Barcelona) ; Servian, Pol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Planas, Jacques (Hospital Universitari Vall d'Hebron) ; Mendez, Olga (Hospital Universitari Vall d'Hebron) ; Esteban, Luis M (Universidad de Zaragoza) ; Trilla Herrera, Enrique (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Early detection of PCa (PCa) has evolved towards clinically significant PCa (csPCa) after the spread of pre-biopsy multiparametric magnetic resonance imaging (mpMRI). However, PCa suspicion remains based on prostate-specific antigen (PSA) elevation and/or abnormal digital rectal examination (DRE). [...]
2022 - 10.3390/cancers14205100
Cancers, Vol. 14 (october 2022)  
3.
9 p, 1.7 MB Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer / Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Borque-Fernando, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Triquell, Marina (Hospital Universitari Vall d'Hebron) ; Campistol, Miriam (Hospital Universitari Vall d'Hebron) ; Servian, Pol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Abascal, Jose Maria (Parc de Salut MAR de Barcelona) ; Planas, Jacques (Hospital Universitari Vall d'Hebron) ; Méndez Fernández, Olga (Hospital Universitari Vall d'Hebron) ; Esteban, Luis M. (Universidad de Zaragoza) ; Trilla Herrera, Enrique (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
The Barcelona magnetic resonance imaging (MRI)-based risk calculator (BCN MRI-RC) exhibited, in the analysed population, better behaviour than the Rotterdam-MRI risk calculator to improve candidate selection for prostate biopsy for the early detection of clinically significant prostate cancer. [...]
2023 - 10.1016/j.euros.2023.03.013
European Urology Open Science, Vol. 53 (may 2023) , p. 46-54  
4.
3 p, 385.5 KB A risk-organised model for clinically significant prostate cancer early detection / Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Borque-Fernando, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Triquell, Marina (Hospital Universitari Vall d'Hebron) ; Abascal, Jose Maria (Parc de Salut MAR de Barcelona) ; Servian, Pol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Planas, Jacques (Hospital Universitari Vall d'Hebron) ; Mendez, Olga (Hospital Universitari Vall d'Hebron) ; Esteban, Luis M. (Universidad de Zaragoza) ; Trilla Herrera, Enrique (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
2023 - 10.1002/bco2.230
BJUI Compass, Vol. 4 (march 2023) , p. 420-422  
5.
16 p, 4.6 MB BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling / Bradbury, Melissa (Centre de Regulació Genòmica) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron) ; Méndez Fernández, Olga (Hospital Universitari Vall d'Hebron) ; Sanchez Iglesias, Jose Luis (Hospital Universitari Vall d'Hebron) ; Pérez-Benavente, Assumpció (Hospital Universitari Vall d'Hebron) ; Gil-Moreno, Antonio 1965- (Centro de Investigación Biomédica en Red de Cáncer) ; Sabidó, Eduard (Centre de Regulació Genòmica) ; Santamaría, Anna (Hospital Universitari Vall d'Hebron) ; Borràs, Eva (Centre de Regulació Genòmica) ; Vall d'Hebron Institut de Recerca (VHIR)
Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. [...]
2022 - 10.1038/s41598-022-08461-0
Scientific reports, Vol. 12 (march 2022)  
6.
14 p, 4.2 MB STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation / Granado-Martínez, Paula (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Ortega, Sara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; González-Sánchez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; McGrail, Kimberley (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Selgas, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ; Gil, Rosa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Naldaiz-Gastesi, Neia (Present Address: Biodonostia, Neurosciences Area, Group of Neuromuscular Diseases) ; Rhodes, Ana C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ; Ferrer, Berta (Hospital Universitari Vall d'Hebron) ; Canals, Francesc (Vall d'Hebron Institut d'Oncologia) ; Villanueva, Josep (Vall d'Hebron Institut d'Oncologia) ; Méndez Fernández, Olga (Vall d'Hebron Institut d'Oncologia) ; Espinosa-Gil, Sergio (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia) ; García-Patos Briones, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Recio Conde, Juan Ángel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. [...]
2020 - 10.1038/s42003-020-1092-0
Communications Biology, Vol. 3 (july 2020)  

Research literature 1 records found  
1.
201 p, 2.8 MB Inhibición de la apoptosis y acúmulo de alteraciones genéticas en la progresión metastásica del cáncer de mama : variabilidad genética y selección poblacional / Méndez Fernández, Olga ; Sierra Jiménez, Àngels, dir. (Institut de Recerca Oncològica)
En un grupo de tumores de mama se decidió estudiar si la pérdida de función de la proteína Bax podía ser debida a la existencia de mutaciones frameshift. Los resultados obtenidos sugieren que en cáncer de mama, las mutaciones del gen bax no serían críticas para la carcinogénesis y el proceso de progresión tumoral. [...]
We studied in a group of breast cancer samples if the loss of function of Bax protein was due to frameshift mutations. Our results show that in breast cancer, bax mutations are not relevant for tumoral progression. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2003  

See also: similar author names
2 Mendez, Olga
1 Mendez, Oscar
1 Méndez, Orlando
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.